NewslettersHepatic Cell NewsCymaBay Completes Enrollment for the RESPONSE Global Phase III Study Evaluating Seladelpar for Patients with Primary Biliary CholangitisBy Danielle Corrigan - August 5, 2022040CymaBay Therapeutics, Inc. announced the completion of enrollment for RESPONSE, a global Phase III study evaluating seladelpar for patients with Primary Biliary Cholangitis.[CymaBay Therapeutics, Inc.]Press Release